Is Alembic Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Alembic Pharmaceuticals Ltd is a good quality company .

Is Alembic Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Alembic Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Alembic Pharmaceuticals share price return in the past 10 years?

Alembic Pharmaceuticals Ltd share price has appreciated 9.6% annually (CAGR) over the past ten years.

Is Alembic Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Alembic Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Alembic Pharmaceuticals?

The latest standalone P/E ratio of Alembic Pharmaceuticals as of 20-Dec-2024 is 26.69.

What is the P/B ratio of Alembic Pharmaceuticals?

The latest standalone P/B ratio of Alembic Pharmaceuticals as of 20-Dec-2024 is 4.12.

What is the 52-week high and low of Alembic Pharmaceuticals?

The 52-week high of Alembic Pharmaceuticals is Rs. 1296.15 and the 52-week low is Rs. 744.95.

Alembic Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Alembic Pharmaceuticals
Brand: Alembic Pharmaceuticals

BSE: 533573 | NSE: APLLTD | Pharmaceuticals & Drugs | Small Cap

Place order

Alembic Pharma Share Price

₹1,055 4.85 0.46%
as on 20-Dec'24 16:59

10 Year X-Ray of Alembic Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	37.5%	65.9%	28.9%	22.2%	22.7%	23.3%	26.3%	11.3%	7.4%	13.4%	-
Value Creation Index ⓘ	1.8	3.9	1.1	0.6	0.7	0.7	1.0	-0.2	-0.5	0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	2,056	3,166	3,135	3,131	3,935	4,606	5,393	5,306	5,653	6,229	6,357
Sales YoY Gr.	-	54%	-1%	-0.1%	25.7%	17.1%	17.1%	-1.6%	6.5%	10.2%	-
Adj EPS ⓘ	14.8	38	21.6	20.7	30.2	45.2	55.3	24.8	17.5	30.5	32.9
YoY Gr.	-	156.6%	-43.1%	-4.3%	46.2%	49.6%	22.6%	-55.2%	-29.4%	74.3%	-
BVPS (₹) ⓘ	46.9	84.7	100.9	117.8	144.2	170.8	257.8	266.5	222.4	245.1	248.7
Adj Net Profit ⓘ	279	715	407	389	569	851	1,088	487	344	600	647
Cash Flow from Ops. ⓘ	172	948	329	312	812	449	1,463	552	724	803	-
Debt/CF from Ops. ⓘ	1.5	0.1	0.3	2.3	1.4	3.9	0.3	1.1	0.9	0.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	13.1%	9.6%	4.9%	10.2%
Adj EPS ⓘ	8.4%	0.2%	-18%	74.3%
BVPSⓘ	20.2%	11.2%	-1.7%	10.2%
Share Price	9.6%	14.1%	11.7%	39.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	35.7	57.7	23.3	18.9	23	28.7	26.3	9.5	7.2	13.1	13.3
Op. Profit Mgn % ⓘ	19.2	31.8	19.8	19.7	21.8	26.4	27.4	16.5	12.6	15	15.8
Net Profit Mgn % ⓘ	13.6	22.6	13.1	12.7	14.7	17.9	19.6	9.2	6.1	9.6	10.2
Debt to Equity ⓘ	0.3	0.1	0.1	0.3	0.4	0.5	0.1	0.1	0.2	0.1	0
Working Cap Days ⓘ	188	146	159	194	182	186	181	192	188	174	97
Cash Conv. Cycle ⓘ	47	16	26	32	38	69	70	88	105	102	46

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 13.30%

Sales growth has been subdued in last 3 years 4.92%

Net Profit has been subdued in last 3 years -18.00%

Sales growth is not so good in last 4 quarters at 6.08%

Latest Financials - Alembic Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	39.5	32.9
TTM Sales (₹ Cr.)	6,119	6,357
BVPS (₹.) ⓘ	256	248.7
Reserves (₹ Cr.) ⓘ	5,212	4,849
P/BV ⓘ	4.12	4.24
PE ⓘ	26.69	32.06

From the Market
52 Week Low / High (₹)	744.95 / 1296.15
All Time Low / High (₹)	34.00 / 1296.15
Market Cap (₹ Cr.)	20,737
Equity (₹ Cr.)	39.3
Face Value (₹)	2
Industry PE ⓘ	44.3

Management X-Ray of Alembic Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Alembic Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Alembic Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	2,056	3,166	3,135	3,131	3,935	4,606	5,393	5,306	5,653	6,229
Operating Expenses ⓘ	1,661	2,161	2,520	2,516	3,079	3,392	3,913	4,432	4,945	5,296
Manufacturing Costs	307	330	354	315	358	471	491	500	561	561
Material Costs	640	824	888	886	993	1,039	1,257	1,446	1,709	1,715
Employee Cost	307	473	559	623	747	906	1,051	1,133	1,169	1,446
Other Costs ⓘ	408	534	720	692	981	975	1,114	1,352	1,506	1,574
Operating Profit ⓘ	395	1,005	615	615	856	1,214	1,480	874	708	933
Operating Profit Margin (%)	19.2%	31.7%	19.6%	19.7%	21.8%	26.4%	27.4%	16.5%	12.5%	15.0%
Other Income ⓘ	12	9	3	35	27	14	87	50	3	29
Interest ⓘ	4	5	5	3	18	27	16	18	50	56
Depreciation ⓘ	44	72	83	105	115	157	183	287	275	273
Exceptional Items ⓘ	0	0	0	0	0	-44	0	0	0	0
Profit Before Tax ⓘ	359	936	529	541	749	1,000	1,368	625	355	632
Tax ⓘ	76	216	122	120	157	199	253	104	13	16
Profit After Tax	283	720	407	421	593	801	1,115	521	342	616
PAT Margin (%)	13.8%	22.7%	13.0%	13.4%	15.1%	17.4%	20.7%	9.8%	6.1%	9.9%
Adjusted EPS (₹)	15.0	38.2	21.4	21.9	31.0	44.0	58.3	26.5	17.4	31.3
Dividend Payout Ratio (%)	23%	10%	19%	18%	18%	23%	24%	38%	46%	35%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	885	1,597	1,902	2,220	2,719	3,219	5,067	5,238	4,370	4,818
Share Capital ⓘ	38	38	38	38	38	38	39	39	39	39
Reserves ⓘ	847	1,560	1,865	2,182	2,681	3,182	5,028	5,198	4,331	4,779
Minority Interest	0	0	0	0	-1	-29	0	0	0	0
Debt	238	114	89	708	928	1,747	200	430	636	430
Long Term Debt	19	0	0	500	499	887	200	0	0	0
Short Term Debt	220	114	89	208	429	861	0	430	636	430
Trade Payables	325	566	501	759	644	626	669	706	680	736
Others Liabilities ⓘ	417	349	319	376	661	628	1,026	856	378	357
Total Liabilities ⓘ	1,865	2,626	2,811	4,064	4,952	6,192	6,961	7,230	6,064	6,341
Fixed Assets
Gross Block	861	1,094	950	1,242	1,523	2,132	2,545	2,840	3,468	3,875
Accumulated Depreciation	314	386	151	249	364	581	757	1,042	1,069	1,329
Net Fixed Assetsⓘ	547	708	799	993	1,158	1,552	1,788	1,798	2,398	2,547
CWIP ⓘ	83	93	396	1,010	1,551	1,846	2,183	2,304	601	524
Investmentsⓘ	2	53	50	42	49	18	236	118	96	93
Inventories	383	570	633	734	967	1,188	1,486	1,610	1,475	1,644
Trade Receivables	361	350	339	526	489	865	349	807	1,046	1,025
Cash Equivalents	27	451	160	90	206	81	106	69	82	127
Others Assetsⓘ	462	400	434	668	532	643	814	523	364	382
Total Assets ⓘ	1,865	2,626	2,811	4,064	4,952	6,192	6,961	7,230	6,064	6,341

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	172	948	329	312	812	449	1,463	552	724	803
PBT ⓘ	359	936	529	541	749	1,000	1,368	625	355	632
Adjustment ⓘ	45	70	83	87	118	278	102	418	488	287
Changes in Working Capital ⓘ	-163	139	-166	-181	112	-593	238	-367	-58	-96
Tax Paid ⓘ	-69	-197	-118	-135	-166	-236	-245	-123	-61	-20
Cash Flow From Investing Activity ⓘ	-256	-307	-486	-884	-756	-732	-839	-372	-448	-321
Capex	-224	-301	-491	-807	-763	-734	-659	-424	-442	-316
Net Investments	-34	-8	4	0	-14	0	-186	48	-7	-8
Others ⓘ	2	2	1	-77	22	3	7	5	1	4
Cash Flow From Financing Activityⓘ	87	-224	-129	503	59	155	-597	-217	-262	-438
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	734	0	0	0
Net Proceeds from Borrowing ⓘ	-37	-39	-5	500	0	0	0	0	0	0
Interest Paid ⓘ	-5	-5	-5	-26	-70	-111	-73	-52	-50	-49
Dividend Paid ⓘ	-65	-79	-90	-91	-91	-326	0	-275	-197	-157
Others ⓘ	194	-101	-29	120	220	592	-1,259	110	-16	-231
Net Cash Flow ⓘ	3	417	-286	-69	115	-128	27	-37	14	45

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	36.24	58.02	23.25	20.42	24	26.97	26.91	10.11	7.12	13.4
ROCE (%)	37.54	65.86	28.87	22.15	22.66	23.3	26.28	11.25	7.44	13.42
Asset Turnover Ratio	1.28	1.41	1.15	0.91	0.87	0.83	0.82	0.75	0.85	1
PAT to CFO Conversion(x)	0.61	1.32	0.81	0.74	1.37	0.56	1.31	1.06	2.12	1.3
Working Capital Days
Receivable Days	56	41	40	50	47	54	41	40	60	61
Inventory Days	61	55	70	80	79	85	90	106	100	91
Payable Days	175	197	219	259	258	223	188	174	148	151

Alembic Pharmaceuticals Ltd Stock News

Alembic Pharmaceuticals Ltd FAQs

What is the share price of Alembic Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Alembic Pharma on 20-Dec-2024 16:59 is ₹1,055.

What is the market cap of Alembic Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Alembic Pharma stood at ₹20,737.4.

What is the P/E ratio of Alembic Pharma?

The latest P/E ratio of Alembic Pharma as of 20-Dec-2024 16:59 is 26.69.

What is the P/B ratio of Alembic Pharma?

The latest P/B ratio of Alembic Pharma as of 20-Dec-2024 16:59 is 4.12.

What is the 52-week high and low of Alembic Pharma?

The 52-week high of Alembic Pharma is ₹1,296.2 and the 52-week low is ₹745.0.

What is the TTM revenue of Alembic Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alembic Pharma is ₹6,119 ( Cr.) .

About Alembic Pharmaceuticals Ltd

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Awards and recognition

Forbes India Awards Mr Pranav Amin and Mr. Shaunak Amin as ‘NextGen Entrepreneurs of the Year’
1st Runner up Position in Job Safety Analysis(JSA) - at CII Industrial Safety Summit 2016
The company’s Commitment towards Risk Management honoured at Gujarat Seminar and Conclave on Risk Management.
The company’s MDs honoured with 'Transformational Leader Award'
The company won 'HR event of the Year' and 'Outstanding contribution to the cause of Education' at the 'Gujarat Best Employer Brand Awards 2017'
The company won 'HR event of the Year' at the 'Gujarat Best Employer Brand Awards 2017'

Milestones

1907: Started manufacturing tinctures and alcohol at Vadodara.
1940: Started manufacturing cough syrup, vitamins, tonics and sulphur drugs.
1961: Lal bahadur Shastri inaugurates the Penicillin plant.
1967: Bulk manufacturing of Vitamin B12.
1971: Erythromycin manufactured for the first time in India.
1972: Althrocin a brand of Erythromycin launched.
1997: Althrocin becomes top selling brand in India.
1999: Alembic starts production of synthetic organic API.
2000: Gets ISO 14000 certification for its facilities at Vadodara.
2001: Starts manufacturing of Cephalosporin C.
2007: Acquisition of non - oncology business of Dabur Pharma Ltd.
2009: Addressed chronic therapies through multiple marketing divisions.
2010: ANDA’s total filed 38. DMF total filed to 53 and get approval for 15.
2011: Pharmaceutical Business demerged from Alembic - APL Listed.
2012: Launched Dermatology division in domestic market with 8 products.
2013: Launched first NDA with a partner. Commenced filing in EU, Australia and Brazil.
2014: Formed a JV in Algeria- Alembic MAMI SPA to explore African market.
2015: Launched Aripiprazole on Day-1. Established the U. S front-end, transition to own marketing in the U.S.
2016: Formed JV 60:40 with Orbicular - “Aleor Dermaceuitical Limited” for developing Dermatology Products for international markets.
2017: Shri. Vijay Rupani - Hon’ble Chief Minister of Gujarat, inaugurates the manufacturing facility for Oncology medicines (oral solids and liquid injectable vials).
2017: Acquired Orit Laboratories LLC, USA.
2018: FDA approved Aleor’s dermatology facility.
2018: Highest ever investment commitment across four new manufacturing facilities.
2019: FDA approves Oncology oral solid facility.
2019: Formed a JV, to enter China.
2020: US front-end achieved milestone of $ 250 Mn Sales in 2019-20.